Back to Search Start Over

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results

Authors :
Alfonso Zaccaria
Francesco Passamonti
Simona Bulgarelli
E. De Biasi
Vincenzo Martinelli
Emma Cacciola
Antonio Tabilio
Anna Candoni
Alessia Tieghi
Alberto Grossi
P. Favini
Roberto Latagliata
Silvia Asioli
Stefano Sacchi
Michele Baccarani
Maurizio Miglino
Luigi Gugliotta
Nicola Vianelli
Serena Rupoli
G. Gardini
Francesco Lauria
G. Pisapia
Gugliotta, L.
Bulgarelli, S.
Tieghi, A.
Asioli, S.
Gardini, G.
Vianelli, N.
Candoni, A.
Latagliata, R.
Rupoli, S.
Martinelli, Vincenzo
Zaccaria, A.
DE BIASI, E.
Sacchi, S.
Lauria, F.
Miglino, M.
Passamonti, F.
Tabilio, A.
Cacciola, E.
Grossi, A.
Pisapia, G.
Favini, P.
Baccarani, M.
Source :
Blood. 104:1523-1523
Publication Year :
2004
Publisher :
American Society of Hematology, 2004.

Abstract

Ninety patients with Essential Thrombocythemia (ET) where object of a phase II prospective multicentre study designed to evaluate efficacy, safety and tolerability of a two years treatment with PEG Interferon α-2b (PEG Intron, Schering Plough). The patients, 30 M and 60 F, 18–72 years old (median 45), observed in 16 Hematological Institutions of the Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC), received the ET diagnosis according to the PVSG criteria. At PEG Intron treatment start the patients showed: previous cytoreduction 97% (IFN α 31%), platelet count >1000 x 109/L 81%, splenomegaly 22%. At the end of the first year The PEG Intron starting dose of 25 μg/week resulted increased to a mean value of 55 μg/week and the Hematological Response (HR = Plts 45 years, platelet count >1000 x109/L, Hb 50 μg/week. In conclusion, the present study shows that in ET patients a two years PEG Intron treatment, able to induce and to maintain the Hematological Response in the majority of cases, is associated to a decrease of bone marrow cellularity, granulopoiesis, erytropoiesis, MK number, size and ploidy and, moreover, with an increase of MK dystrophy and of bone marrow fibrosis. These preliminary data on bone biopsy and aspirate will be object of a planned centralized reevaluation by a Panel of Pathologists and Clinicians.

Details

ISSN :
15280020 and 00064971
Volume :
104
Database :
OpenAIRE
Journal :
Blood
Accession number :
edsair.doi.dedup.....8454898903336cc8bf2ba77e12042aa4
Full Text :
https://doi.org/10.1182/blood.v104.11.1523.1523